Pediatric multiple sclerosis on the rise


  • Mridul Soni Department of Pediatrics, Shri Lal Bahadur Shastri Government Medical College, Himachal Pradesh, India
  • Dilkanwal Singh Deol Department of Pediatrics, Shri Lal Bahadur Shastri Government Medical College, Himachal Pradesh, India
  • Aditi Goyal Department of Pediatrics, Shri Lal Bahadur Shastri Government Medical College, Himachal Pradesh, India



Acute disseminated encephalomyelitis, Magnetic resonance imaging, Methylprednisolone, Cerebrospinal fluid, Adolescent female


The development of multiple sclerosis in children provides to have prophylactic and treatment problems, especially if the manifestations of the initial demyelinating episode mirror the acute disseminated encephalomyelitis. This disease which was once considered a rare occurrence has started to show more cases in the last few years. Magnetic resonance imaging seems to be an excellent diagnostic technique but it is limited because of the accuracy to identify acute disseminated encephalomyelitis from the initial bout of multiple sclerosis. Sophisticated magnetic resonance imaging methods could provide the needed precision to identify if the degradation and consistency of non-lesional matter can be differentiated for what happens as a core hallmark of multiple sclerosis. Even though the development of multiple sclerosis in infancy often forecasts a positive short-term outcome, several children become seriously impaired, whether physically or intellectually, and much more than fifty percent are anticipated to reach the secondary-progressive stage of the illness by the age of thirty years. Immunomodulatory treatments for multiple sclerosis and its therapeutic administration in adolescents may enhance long-term outcomes. Environmental and genetic variables, including viral infection, could be especially suitable for investigation in juvenile individuals with multiple sclerosis. Addressing the immunological effects of these exposures should offer insight into the early clinical manifestations and correct diagnosis of multiple sclerosis.


Absoud M, Lim M, Chong W, DeGoede C, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Multiple Scler J. 2012;19(1):76-86.

Banwell B, Kennedy J, Sadovnick D, Arnold D, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232-9.

Ketelslegers I, Catsman-Berrevoets C, Neuteboom R, Boon M, Dijk K, Eikelenboom M, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol. 2012;259(9):1929-35.

Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol. 2007;6(10):887-902.

Mikaeloff Y, Caridade G, Assi S, Suissa S, Tardieu M. Prognostic factors for early severity in a childhood multiple sclerosis COHORT. Pediatrics. 2006;118(3):1133-9.

Ahn J, O’Mahony J, Moshkova M, Hanwell H, Singh H, Zhang M, et al. Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. Multiple Sclerosis J. 2014;21(6):735-48.

Krupp L, Tardieu M, Amato M, Banwell B, Chitnis T, Dale R, et al. International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis J. 2013;19(10):1261-7.

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.

Ghezzi A, Pozzilli C, Liguori M, Marrosu M, Milani N, Milanese C, et al. Prospective study of multiple sclerosis with early onset. Multiple Sclerosis J. 2002;8(2):115-8.

Reinhardt K, Weiss S, Rosenbauer J, Gärtner J, von Kries R. Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011). Eur J Neurol. 2014;21(4):654-9.

Wong Y, Vries R, Pelt E, Ketelslegers I, Melief M, Wierenga A, et al. T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes. Multiple Sclerosis J. 2018;24(13):1715-24.

Calabresi P, Arnold D, Sangurdekar D, Singh C, Altincatal A, de Moor C, et al. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Multiple Sclerosis J. 2020;27(10):1497-505.

Mikaeloff Y. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004;127(9):1942-7.

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.

Waubant E, Chabas D, Okuda D, Glenn O, Mowry E, Henry R, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009;66(8).

Aubert-Broche B, Fonov V, Ghassemi R, Narayanan S, Arnold D, Banwell B, et al. Regional brain atrophy in children with multiple sclerosis. Neuro Image. 2011;58(2):409-15.

Gorman M, Healy B, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1).

Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N E J Med. 2007;356(25):2603-13.

Disanto G, Magalhaes S, Handel A, Morrison K, Sadovnick A, Ebers G, et al. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology. 2011;76(9):781-6.

Pelt E, Mescheriakova J, Makhani N, Ketelslegers I, Neuteboom R, Kundu S, et al. Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology. 2013;81(23):1996-2001.

Mowry E, Krupp L, Milazzo M, Chabas D, Strober J, Belman A, et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol. 2010.

Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, Lehnert M, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 2006;67(11):2063-5.

Cobo-Calvo Á, Ruiz A, D’Indy H, Poulat A, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017;264(9):1945-55.

Hacohen Y, Wong Y, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease. JAMA Neurol. 2018;75(4):478.

Amato M. Cognitive impairment in early-onset multiple sclerosis. Arch Neurol. 1995;52(2):168.

Holland A, Graves D, Greenberg B, Harder L. Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis. Child Neuropsychology. 2012;20(1):71-85.

Weisbrot D, Charvet L, Serafin D, Milazzo M, Preston T, Cleary R, et al. Psychiatric diagnoses and cognitive impairment in pediatric multiple sclerosis. Multiple Sclerosis J. 2013;20(5):588-93.

Mowry E, Loguidice M, Daniels A, Jacobs D, Markowitz C, Galetta S, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatr. 2009;80(7):767-72.

Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis J. 2011;18(1):116-27.

Banwell B, Reder A, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472-6.

Chitnis T, Arnold D, Banwell B, Brück W, Ghezzi A, Giovannoni G, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N E J Med. 2018;379(11):1017-27.






Review Articles